A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Inclusion Criteria

• •1. Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
• •2. Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody and participant should meet indication for treatment, as described in the protocol.
• •3. Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography \[CT\], or Magnetic Resonance Imaging \[MRI\] imaging, as described in the protocol.
• •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• •5. Adequate hematologic and organ function, as described in the protocol.
• •6. All study participants must:
• •1. Have an understanding that lenalidomide could have a potential teratogenic risk.
• •2. Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
• •3. Agree not to share study medication with another person.
• •4. Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide.